Anterogen

Anterogen is a bio-venture company specializing in research and development of cell therapy products and orphan drugs using adult stem cells. Established in 2000 with a research institute in Boston, the company began commercializing products using adipose-derived stem cells for the first time in Korea. In January 2012, Anterogen obtained market authorization of Cupistem® injection as an adipose-derived stem cell therapy product, marking a global first. With a focus on biotechnology and pharmaceutical industries, Anterogen has developed Adipocell®, Queencell®, and Cupistem® injection, leveraging accumulated experiences and R&D technology in stem cell therapy. The company recently received a post-IPO equity investment on 01 January 2022 from Company K Partners, DAYLI Partners, Shinhan Venture Investment, and Hyundai Venture Investment Corporation.